Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME3BJL)

• Drug Name: PF-07062119 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DME3BJL

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[6]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[7]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[8]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[9]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[10]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[11]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[12]

Drug(s) Targeting Guanylyl cyclase C (GUCY2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Linaclotide	DM4EGV0	Irritable bowel syndrome	DD91.0	Approved	[13]
MD-1100	DM4IAKR	Constipation	DD91.1	Approved	[14]
Plecanatide	DMKEX7O	Chronic idiopathic constipation	DC32	Approved	[15]
SP-333	DM2UKJV	Ulcerative colitis	DD71	Phase 2	[16]
MLN0264	DMI4E9K	Gastrointestinal cancer	2C11	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Guanylyl cyclase C (GUCY2C)	TTLDPRG	GUC2C_HUMAN	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04171141) Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.. U.S. National Institutes of Health.
• [2] Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [5] Clinical pipeline report, company report or official report of Genmab.
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [7] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [8] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [9] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [10] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [11] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [12] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [13] Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
• [14] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] J Clin Oncol 31, 2013 (suppl; abstr TPS3646).